Introduction
The year 2011 marked 30 years since the first index cases of AIDS were reported. Due to the increased life expectancy of HIV-positive individuals, the influx of people living with HIV into the UK and ongoing local transmission, the prevalence of HIV continues to rise nationally.
By the end of 2010, there were 91,500 people in the UK estimated to be HIV-positive, with 24% of these remaining undiagnosed. In the same year, 6,660 new diagnoses of HIV were made, with 50% of these diagnoses being made late (ie when CD4 counts were <350 cells/mm 3 ). 1 National efforts to improve testing rates have resulted in a fall in the proportion of infected but undiagnosed individuals. At present, there are broad national guidelines for HIV testing 2 but there is no current guideline for HIV testing specific to the unique environment and patient population of intensive care units (ICUs) in England.
The purpose of this survey was to determine current HIV testing practices and attitudes to testing in English ICUs. Following consultation with the Intensive Care Society (ICS), a national survey was performed via ICS linkmen in all 120 participating ICUs in England. The survey opened in August 2011 and closed at the end of October 2011. At the time of completion, 53 (44%) centres had replied.
Guidelines
Five of 53 (9%) centres reported having written guidelines for HIV testing. Four of these incorporated national HIV testing guidelines. The other centre based testing upon specialist advice only. Four of the centres with written guidelines intended to continue testing for at least the next 12 months; one was unsure if they would continue.
ICUs without HIV testing guidelines
Forty-eight of 53 (91%) units did not have written guidelines. Ten (21%) had discussed introducing formal HIV testing guidelines, and three of these intended to introduce formal guidelines within the next 12 months.
Of the centres without written guidelines, seven of 48 (15%) reported using present national guidelines as a basis for testing and a further four (8%) stated they only test on specialist advice.
The centres without written guidelines were given a list of eight diseases, and asked to state which of these triggered testing for HIV. These were all HIV-indicator diseases published in national guidelines. Eight centres did not respond. Three centres stated they would not routinely test for HIV for any of the diseases; this included two that had stated they test only on specialist advice.
Thirty-seven of 48 (77%) ICUs tested for HIV in the presence of at least one of the indicator diseases. All 37 centres tested for HIV in the context of unexplained opportunistic infection and 27 of 48 (56%) routinely tested for HIV in the presence of pulmonary tuberculosis (TB). A further 10 of 48 (21%) tested for HIV with diagnosed lymphoma. For each of the remaining indicator illnesses (lung cancer, Guillian-Barré syndrome, aseptic meningitis, bacterial pneumonia, explained opportunistic infection), fewer than 10 of 48 (21%) centres tested routinely for HIV.
No ICU performed HIV tests for all the indicator diseases listed in the survey. Of the seven units without formal written guidelines who used national guidelines as a basis for HIV testing, one reported a 75% testing compliance rate, another 50%, another 37%, and the remaining four centres had 25% testing compliance rates for the eight specified indicator illnesses in the survey.
Attitudes towards current regulation
The survey explored attitudes towards the regulation of HIV testing. A majority, 30 of 53 (57%), of responders believed the
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Audits and surveys
General Medical Council (GMC) regulations should be changed to allow for global testing of HIV in ICU patients lacking capacity, irrespective of their diagnosis and 37 of 53 (70%) agreed that critical illness should be nationally recognised as an indicator disease for HIV.
Almost all (49 of 53 -92%) supported a change to GMC regulations to allow for HIV testing of ICU patients lacking capacity when a member of staff suffers a needlestick injury related to the care of the patient. In contrast, 19 of 53 (36%) felt that current GMC regulations and national HIV testing guidelines were sufficient and no changes were required.
Discussion
In 2011, the Health Protection Agency (HPA) released its final report 'Time to test for HIV: Expanding HIV testing in healthcare and community services in England.' 3 The report received financial support from the Department of Health and set the scene for expanding HIV testing within the UK Health Service.
'Time to Test' included eight pilot studies of HIV testing. Three hospital-based studies involved opt-out testing in three medical admissions units and one accident and emergency department. High levels of patient acceptability were observed in these settings, with an uptake rate of 62-91%. A consistent problem reported in the pilot studies was low test-offer rates (21-62%). This reflected time pressures, staff education and staff reluctance to offer the test. 3 The latter is a barrier to HIV testing which has been previously demonstrated among ICU staff. 4 The pilot studies indicated that there was a large variation in the demographics of patients likely to be offered a test and in testing rates among clinical staff. Despite these limitations, the studies resulted in new diagnoses of HIV in patients who would have otherwise remained undiagnosed.
The trend to offer opt-out testing is growing, but is not a viable model within the intensive care setting, since the majority of critically ill patients lack the mental capacity to make informed decisions about their care. For these patients, standards of care are governed by GMC guidance 5,6 and legislation. The Mental Capacity Act 2005 provides the central legal framework for doctors making clinical decisions on behalf of patients lacking mental capacity. When testing for HIV in these patients, other legislation in the Human Tissue Act 2004 and the Human Rights Act 1998 must also be considered. Management decisions made on behalf of patients lacking capacity must provide clinical benefit and must be made on their behalf only when immediately necessary to save life or to prevent a serious deterioration of their condition. The treatment provided must be the least restrictive of the patient' s future choices. When an HIV test is considered during a critical illness, it is difficult to argue that knowing the result would not provide clinical benefit and it may be deemed necessary to prevent serious deterioration.
Subsequent clinical information may change the differential diagnosis, enable early specialist input, inform decisions involving potentially harmful drugs and allow the prompt initiation of potentially life-saving treatment. However, the principle of avoiding restriction of future choices may be compromised if a test is performed and a patient who later regains competence does not wish to know the result. This argument holds for many tests already performed on ICU patients and while the prognosis for appropriately diagnosed and treated HIV or its complications is likely to be favourable in the era of highly-active antiretroviral treatment (HAART), the prognosis for other diseases may be much less optimistic.
There are several proposed models of HIV testing in patients lacking mental capacity to consent.
The first option: universal testing
This survey indicates that 57% of those responding support this option. HIV is no longer a disease confined to specific patient groups. The concept of an 'at risk' patient is now superseded by the concept that 'everyone is at risk.' Human behaviour is complex, unpredictable and multifaceted. Many patients will not disclose previous risk behaviours to doctors or to their partners and families. Focusing on only testing high risk groups will inevitably lead to missed diagnoses.
Targeted HIV testing of patients with specific indicator illnesses form the basis of the present national guidelines, but the list is not exhaustive and the presence of these indicator illnesses may be associated with a late HIV diagnosis. This carries a tenfold risk of death in the following year compared to those diagnosed with early HIV. 1 Universal testing overcomes many of the limitations associated with targeted testing strategies.
In addition to anticipating improved patient outcomes, evidence from sexual health clinics, antenatal clinics and the three hospital studies in 'Time to Test' suggests widespread public acceptance of HIV testing. This acceptance may be even higher in the context of a life-threatening event.
National guidelines support universal testing only when the prevalence in a region' s general population exceeds 2 per 1,000 (0.2%). There are ICUs within the UK which already serve populations in which the prevalence of HIV exceeds this level. This demarcation of 0.2% is based on Quality Adjusted Life Years (QALY) and economic analysis derived from USA data in a general population. This may have little relevance to an intensive care population in the UK. Although cost analysis and cost-effectiveness were considered in 'Time to Test,' it is difficult to translate research costs into clinical costs incurred in roll-out programmes. Cost savings were likely (in terms of QALYs) if increased testing rates led to earlier diagnosis. 3 Delayed diagnosis of HIV is likely to lead to significantly higher ongoing care costs on ICUs. The anticipated cost savings may support measures to improve earlier diagnosis in this setting.
The second option: targeted testing
In this survey, global testing was not universally accepted, with 19 of 53 respondents (36%) believing present guidelines to be adequate. When focusing on targeted testing, GMC guidance to provide treatment with 'overall clinical benefit' to those patients lacking capacity is open to interpretation and may result in conflicting opinion among physicians. Delaying targeted testing in circumstances where patients may regain capacity may delay appropriate acute management. An assessment must be made on a case-by-case basis whether immediate testing and subsequent treatment will avoid a serious deterioration in an individual' s condition. Such a judgment may only be possible in hindsight and may be too late for the undiagnosed, HIV-positive individual.
Eleven (21%) of the 53 ICUs (seven without and four with written guidelines) in this survey used the national HIV testing guidelines as the basis for assessing whether an HIV test would provide overall clinical benefit. Despite employing the existing national guidelines, testing compliance was usually low and never greater than 75%. In addition to the list of AIDS-defining and HIV indicator diseases a test is recommended for all patients on haemodialysis, men who have sex with men (MSM) and patients from countries with an HIV prevalence of >1%. The national guidelines are targeted at a wide audience in the community, general practice, hospital outpatients and acute admissions. However, there are specific limitations in translating these guidelines for use in the ICU setting.
The list of triggers for testing is complex and would require a continued and committed programme of education and promotion among ICU staff. A wide range of clinical presentations is observed in ICU and the list of indicator illnesses is not exhaustive. Establishing many of the testing criteria requires a personal, in-depth history, which is unavailable from most ICU patients. Bacterial pneumonia is an HIV indicator disease: should all patients with hospital-and ventilator-acquired pneumonia be tested? Do all patients receiving renal support require a test or just those receiving haemodialysis? Who is responsible for triggering a test? The national guidelines suggest 'any doctor, midwife, nurse or trained healthcare worker' should be able to test, but more clinical judgment is required when consent cannot be obtained. Would the decision to test for HIV have to be made by a physician? Variation in testing rates among clinicians has been demonstrated. 3, 4 If targeted testing is to be used in ICUs, there is a clear need for national guidelines specific to the nature and needs of the unique clinical setting. Any guideline based on targeted testing must be applicable to units serving high and low prevalence populations and be accompanied by a continued package of promotion and education for all ICU staff. This seems a complex and arduous route to expanding HIV testing in intensive care, but would provide an agreed framework for acting in absolute accordance with the present regulations.
A third option: critical illness in the ICU as an indicator illness for HIV infection
A study examining 1,052 patient admission records (all admissions during 2010) to two general ICUs in Sheffield was undertaken (in press, Dodd M, Collini P, 2011). With stringent application of the National HIV Testing Guidelines, 30% of admissions fulfilled the criteria for an HIV test in each of the units. With this level of testing recommended, it is arguable that 'critical illness in ICU' should be an HIV indicator disease in itself. This may be interpreted as universal testing by proxy. This survey showed 70% of responders supported this approach in the ICU setting.
Non-clinical reasons for HIV testing
Routine screening for MRSA is beneficial for the Trust as well as for the patient and from a clinical governance stance. There is similar merit in knowing a patient' s HIV status. This is particularly poignant in ICU where invasive procedures are undertaken and there is a continuous need for handling of patients' blood and the use of 'sharps'. Following contaminated needlestick injury, there is a great deal of anxiety for staff when a patient lacking capacity cannot be tested for HIV under present legislation and GMC guidance. 7 To carry out an HIV test in this context is an infringement of the law, defined in the Human Tissue Act 2004. In clinical practice, patients who are the source of needlestick injuries who possess capacity usually consent to an HIV test. Post-exposure prophylaxis (PEP) is not without hazard and it is difficult to see how an informed risk assessment can be made without knowing the HIV status of the patient. There is a strong argument both morally and within the legislation of the Human Rights Act 7 for changes to the current GMC guidance and to legislation. Ninety-two percent of those completing the survey supported such a change to current regulations to allow HIV testing of patients lacking mental capacity to consent when a needlestick injury is sustained by a member of staff.
'Time to Test' did not include a pilot study within an intensive care setting and perhaps an opportunity was missed. It did highlight the need and reasons to increase HIV testing and to consider all individuals as being at risk of HIV infection.
This national survey describes a wide variation in testing practices in the absence of any ICU-specific HIV testing guidelines. A majority of centres following national guidelines reported poor compliance with HIV testing in patients with indicator illnesses. This indicates a deficit in education and promotion, hesitance when considering who and when to test and reluctance of staff to initiate or take responsibility for testing. This latter point reflects concerns regarding the continuing stigma associated with HIV infection.
Conclusion
To provide gold standard patient care, the ICU community should consider how best to increase national HIV testing rates. To support clinicians in their decision to test, there is a need for national HIV testing guidelines specific to intensive care. The current national guidelines provide an excellent framework from which to develop targeted testing specific to ICU, but there are many unresolved questions.
Universal testing may offer a pragmatic approach, be logistically easier to implement than targeted testing and benefit the majority, patients, staff and those who may escape onward transmission in the community. Universal testing is likely to identify more HIV diagnoses than targeted testing. This global screening approach benefits not only those whose HIV diagnosis is expedited but also the vast majority whose care can be better planned in the context of a negative result. There is likely to be economic benefit in screening for HIV in ICUs. Universal and targeted HIV testing are possible but will require support from the General Medical Council and from specialist bodies such as the Intensive Care Society, the British
